Anne M Porzig, MD
Endocrinology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Offices
- 2
Offices
2 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Porzig’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A99582 · Current
Licensed to practise in California · since 2007 · expires 2026-09-30 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$89,308
Medicare paid this office $89,308 for 240 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 14 | $27,243 | None |
| Return visit (30+ min) | 134 | $19,743 | $109 |
| Long return visit (40+ min) | 70 | $12,919 | $161 |
| New patient visit (45+ min) | 22 | $3,489 | $159 |
| Short return visit (20+ min) | 39 | $3,473 | $79 |
See all 8 services
| Injection, denosumab, 1 mg | 14 | $27,243 | None |
| Return visit (30+ min) | 134 | $19,743 | $109 |
| Long return visit (40+ min) | 70 | $12,919 | $161 |
| New patient visit (45+ min) | 22 | $3,489 | $159 |
| Short return visit (20+ min) | 39 | $3,473 | $79 |
| New patient visit (60+ min) | 17 | $3,251 | $191 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 22 | $3,226 | $134 |
| Injection of drug or substance under skin or into muscle | 20 | $560 | $14 |
Who their Medicare patients are
240 Original Medicare patients in 2024. Average age 76 · Women 72% · Also on Medicaid 5% · Health risk score 1.04. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 55% · Diabetes 33% · Chronic kidney disease 23% · Coronary heart disease 22% · Cancer 18% · Depression 14% · Atrial fibrillation 13% · Heart failure 8% · COPD 7% · Stroke 5%.
The office billed $273,299, Medicare allowed $115,198 and paid $89,308; for 3,592 services of 18 kinds; $41,522 of it was for drugs given in the office and $47,786 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 240 | 3,592 | 76 | 1.04 | $273,299 | $89,308 |
| 2023 | 237 | 3,534 | 76 | 0.94 | $217,624 | $71,409 |
| 2022 | 218 | 3,100 | 76 | 1.04 | $166,009 | $53,757 |
| 2021 | 221 | 3,024 | 76 | 0.99 | $140,722 | $46,640 |
| 2020 | 174 | 2,393 | 75 | 1.06 | $96,905 | $29,268 |
| 2019 | 212 | 3,386 | 75 | 1.03 | $147,615 | $42,036 |
| 2018 | 202 | 1,332 | 73 | 1.12 | $159,212 | $43,395 |
| 2017 | 149 | 644 | 75 | 1.05 | $114,756 | $31,043 |
| 2016 | 132 | 387 | 74 | 1.05 | $76,077 | $20,224 |
| 2015 | 185 | 549 | 72 | 1.04 | $149,734 | $39,949 |
| 2014 | 143 | 356 | 73 | 1.01 | $111,634 | $27,689 |
| 2013 | 111 | 263 | 73 | 1.26 | $80,994 | $23,287 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 140 | $20,108 | $117 |
| Long return visit (40+ min) | 67 | $13,081 | $164 |
| New patient visit (60+ min) | 17 | $3,248 | $191 |
| Short return visit (20+ min) | 26 | $2,161 | $77 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 13 | $1,807 | $139 |
| New patient visit (45+ min) | 12 | $1,776 | $148 |
| Injection of drug or substance under skin or into muscle | 12 | $504 | $14 |
2022: 6 services
| Return visit (30+ min) | 136 | $20,831 | $115 |
| Long return visit (40+ min) | 48 | $10,003 | $170 |
| New patient visit (60+ min) | 26 | $5,341 | $205 |
| Short return visit (20+ min) | 45 | $3,910 | $80 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 14 | $2,124 | $142 |
| Injection of drug or substance under skin or into muscle | 11 | $391 | $13 |
2021: 6 services
| Return visit (30+ min) | 119 | $18,455 | $115 |
| Long return visit (40+ min) | 36 | $6,228 | $156 |
| Short return visit (20+ min) | 56 | $5,813 | $88 |
| New patient visit (45+ min) | 24 | $3,516 | $146 |
| New patient visit (60+ min) | 15 | $2,973 | $198 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 16 | $2,212 | $138 |
2020: 5 services
| Return visit (30+ min) | 93 | $11,167 | $97 |
| Short return visit (20+ min) | 55 | $4,101 | $70 |
| Long return visit (40+ min) | 12 | $1,957 | $140 |
| New patient visit (45+ min) | 13 | $1,877 | $144 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 11 | $396 | $33 |
2019: 7 services
| Return visit (30+ min) | 102 | $13,262 | $98 |
| Short return visit (20+ min) | 92 | $7,552 | $65 |
| Long return visit (40+ min) | 34 | $5,948 | $135 |
| New patient visit (45+ min) | 22 | $3,343 | $152 |
| New patient visit (60+ min) | 17 | $3,292 | $194 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 11 | $1,617 | $124 |
| Injection of drug or substance under skin or into muscle | 11 | $459 | $16 |
2018: 7 services
| Return visit (30+ min) | 82 | $12,296 | $98 |
| Short return visit (20+ min) | 85 | $7,299 | $66 |
| New patient visit (45+ min) | 36 | $5,502 | $153 |
| Long return visit (40+ min) | 19 | $2,677 | $134 |
| Fine needle aspiration using imaging guidance | 15 | $2,373 | $140 |
| New patient visit (30+ min) | 22 | $2,209 | $100 |
| Ultrasonic guidance for needle placement | 15 | $940 | $59 |
2017: 6 services
| Return visit (30+ min) | 90 | $11,208 | $93 |
| Long return visit (40+ min) | 25 | $4,174 | $130 |
| Short return visit (20+ min) | 46 | $3,695 | $67 |
| Fine needle aspiration using imaging guidance | 13 | $1,948 | $139 |
| New patient visit (45+ min) | 14 | $1,841 | $132 |
| Ultrasonic guidance for needle placement | 13 | $766 | $59 |
2016: 4 services
| Return visit (30+ min) | 60 | $6,956 | $95 |
| Short return visit (20+ min) | 55 | $4,076 | $61 |
| Long return visit (40+ min) | 21 | $3,202 | $133 |
| New patient visit (45+ min) | 11 | $1,405 | $128 |
2015: 7 services
| Return visit (30+ min) | 94 | $12,604 | $101 |
| Long return visit (40+ min) | 41 | $6,765 | $141 |
| Fine needle aspiration using imaging guidance | 27 | $5,684 | $146 |
| Short return visit (20+ min) | 61 | $4,878 | $69 |
| New patient visit (45+ min) | 26 | $3,732 | $144 |
| Ultrasonic guidance for needle placement | 26 | $1,830 | $61 |
| New patient visit (30+ min) | 16 | $1,697 | $106 |
2014: 6 services
| Return visit (30+ min) | 64 | $8,507 | $98 |
| Short return visit (20+ min) | 46 | $4,289 | $65 |
| Fine needle aspiration using imaging guidance | 26 | $4,218 | $136 |
| New patient visit (30+ min) | 40 | $3,573 | $89 |
| New patient visit (45+ min) | 17 | $2,460 | $145 |
| Ultrasonic guidance for needle placement | 26 | $2,013 | $72 |
2013: 7 services
| Return visit (30+ min) | 51 | $6,208 | $94 |
| Ultrasonic guidance for needle placement | 16 | $3,191 | $199 |
| Short return visit (20+ min) | 29 | $2,823 | $66 |
| New patient visit (45+ min) | 19 | $2,509 | $132 |
| Fine needle aspiration using imaging guidance | 16 | $2,428 | $135 |
| New patient visit (30+ min) | 25 | $2,300 | $92 |
| Long return visit (40+ min) | 13 | $2,152 | $127 |
Medicaid work
$1,099 in 2023
Medicaid paid $1,099 for 26 billed services this clinician did in 2023, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 26 | $1,099 |
| 2023 | 26 | 1 | 13 | $1,099 |
Drugs they prescribed that Part D paid
$364,657
Pharmacies billed $364,657 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,070) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
610 generic and 409 brand-name prescriptions · $364,657 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tymlos | 28 | $80,858 | $2,888 |
| Rybelsus | 37 | $63,994 | $1,730 |
| Jardiance | 55 | $59,365 | $1,079 |
| Mounjaro | 32 | $33,478 | $1,046 |
| Ozempic | 14 | $14,834 | $1,060 |
See all 22 drugs
| Tymlos | 28 | $80,858 | $2,888 |
| Rybelsus | 37 | $63,994 | $1,730 |
| Jardiance | 55 | $59,365 | $1,079 |
| Mounjaro | 32 | $33,478 | $1,046 |
| Ozempic | 14 | $14,834 | $1,060 |
| Afrezza | 17 | $13,450 | $791 |
| Tresiba Flextouch U-100 | 16 | $10,062 | $629 |
| Synthroid | 42 | $5,284 | $126 |
| Metformin | 42 | $3,350 | $80 |
| Lantus Solostar | 13 | $2,375 | $183 |
| Levothyroxine | 172 | $1,939 | $11 |
| Alendronate | 168 | $1,499 | $9 |
| Liothyronine | 38 | $1,383 | $36 |
| Nano 2nd Gen Pen Needle | 20 | $1,326 | $66 |
| Metformin Hcl Er | 61 | $892 | $15 |
| Lantus | 12 | $870 | $73 |
| Atorvastatin | 51 | $601 | $12 |
| Losartan | 23 | $255 | $11 |
| Methimazole | 22 | $168 | $8 |
| Simvastatin | 16 | $151 | $9 |
| Lisinopril | 11 | $107 | $10 |
| Rosuvastatin | 11 | $16 | $1 |
Year by year
| 2024 | 1,070 | 178 | 0% (0) | 38% | $364,657 |
| 2023 | 1,038 | 163 | 0% (0) | 43% | $534,557 |
| 2022 | 955 | 157 | 0% (0) | 42% | $532,500 |
| 2021 | 874 | 143 | 0% (0) | 39% | $369,971 |
| 2020 | 835 | 132 | 0% (0) | 38% | $250,115 |
| 2019 | 822 | 132 | 0% (0) | 39% | $259,045 |
| 2018 | 718 | 111 | 0% (0) | 37% | $195,185 |
| 2017 | 606 | 104 | 0% (0) | 40% | $169,817 |
| 2016 | 692 | 101 | 0% (0) | 38% | $180,115 |
| 2015 | 543 | 86 | 0% (0) | 48% | $121,352 |
| 2014 | 451 | 65 | 0% (0) | 48% | $107,232 |
| 2013 | 307 | 56 | 0% (0) | 56% | $54,892 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 22 drugs
| Forteo | 18 | $86,124 | $4,785 |
| Rybelsus | 42 | $75,686 | $1,802 |
| Jardiance | 62 | $73,632 | $1,188 |
| Teriparatide | 17 | $45,480 | $2,675 |
| Ozempic | 29 | $38,356 | $1,323 |
| Tymlos | 12 | $33,175 | $2,765 |
| Humalog Kwikpen U-100 | 18 | $17,406 | $967 |
| Lantus Solostar | 18 | $15,703 | $872 |
| Tresiba Flextouch U-100 | 21 | $14,767 | $703 |
| Mounjaro | 11 | $13,345 | $1,213 |
| Synthroid | 31 | $3,848 | $124 |
| Levothyroxine | 136 | $2,331 | $17 |
| Ultra-Fine Nano Pen Needle | 18 | $2,209 | $123 |
| Metformin Hcl Er | 75 | $1,884 | $25 |
| Alendronate | 166 | $1,801 | $11 |
| Nano 2nd Gen Pen Needle | 23 | $1,550 | $67 |
| Liothyronine | 25 | $1,455 | $58 |
| Atorvastatin | 49 | $681 | $14 |
| Metformin | 36 | $536 | $15 |
| Losartan | 14 | $434 | $31 |
| Methimazole | 16 | $204 | $13 |
| Simvastatin | 15 | $118 | $8 |
2022: 23 drugs
| Forteo | 31 | $132,132 | $4,262 |
| Jardiance | 59 | $70,666 | $1,198 |
| Rybelsus | 25 | $51,344 | $2,054 |
| Tymlos | 20 | $49,531 | $2,477 |
| Ozempic | 31 | $38,600 | $1,245 |
| Teriparatide | 11 | $29,512 | $2,683 |
| Humalog Kwikpen U-100 | 16 | $25,819 | $1,614 |
| Lantus Solostar | 20 | $16,922 | $846 |
| Tresiba Flextouch U-100 | 16 | $16,440 | $1,028 |
| Lantus | 13 | $6,458 | $497 |
| Synthroid | 25 | $3,021 | $121 |
| Levothyroxine | 111 | $2,363 | $21 |
| Liothyronine | 21 | $1,662 | $79 |
| Ultra-Fine Nano Pen Needle | 11 | $1,604 | $146 |
| Nano 2nd Gen Pen Needle | 18 | $1,438 | $80 |
| Alendronate | 150 | $1,408 | $9 |
| Metformin Hcl Er | 74 | $1,246 | $17 |
| Ultra-Fine Mini Pen Needle | 12 | $972 | $81 |
| Atorvastatin | 36 | $513 | $14 |
| Metformin | 39 | $225 | $6 |
| Methimazole | 15 | $165 | $11 |
| Simvastatin | 14 | $104 | $7 |
| Lisinopril | 12 | $72 | $6 |
2021: 21 drugs
| Jardiance | 50 | $63,268 | $1,265 |
| Tymlos | 22 | $50,763 | $2,307 |
| Forteo | 12 | $46,436 | $3,870 |
| Rybelsus | 18 | $25,755 | $1,431 |
| Lantus Solostar | 30 | $24,247 | $808 |
| Ozempic | 22 | $24,139 | $1,097 |
| Tradjenta | 17 | $22,919 | $1,348 |
| Humalog Kwikpen U-100 | 14 | $17,012 | $1,215 |
| Trulicity | 12 | $10,768 | $897 |
| Synthroid | 22 | $2,516 | $114 |
| Levothyroxine | 104 | $2,475 | $24 |
| Ultra-Fine Nano Pen Needle | 13 | $1,734 | $133 |
| Nano 2nd Gen Pen Needle | 15 | $1,574 | $105 |
| Metformin | 42 | $1,512 | $36 |
| Liothyronine | 22 | $1,386 | $63 |
| Alendronate | 129 | $1,258 | $10 |
| Metformin Hcl Er | 63 | $1,099 | $17 |
| Ultra-Fine Mini Pen Needle | 15 | $1,078 | $72 |
| Atorvastatin | 28 | $446 | $16 |
| Methimazole | 20 | $186 | $9 |
| Simvastatin | 14 | $77 | $5 |
2020: 22 drugs
| Forteo | 13 | $45,888 | $3,530 |
| Tymlos | 12 | $27,796 | $2,316 |
| Jardiance | 24 | $27,549 | $1,148 |
| Lantus Solostar | 38 | $23,521 | $619 |
| Tradjenta | 15 | $18,376 | $1,225 |
| Humalog Kwikpen U-100 | 13 | $15,156 | $1,166 |
| Afrezza | 12 | $7,472 | $623 |
| Lantus | 11 | $5,461 | $496 |
| Synthroid | 44 | $4,272 | $97 |
| Ultra-Fine Nano Pen Needle | 34 | $3,179 | $94 |
| Levothyroxine | 114 | $3,085 | $27 |
| Metformin Hcl Er | 66 | $1,725 | $26 |
| Repaglinide | 11 | $1,265 | $115 |
| Liothyronine | 26 | $1,242 | $48 |
| Alendronate | 102 | $1,199 | $12 |
| Methimazole | 29 | $346 | $12 |
| Atorvastatin | 20 | $335 | $17 |
| Metformin | 27 | $290 | $11 |
| Amlodipine Besylate | 12 | $111 | $9 |
| Losartan | 11 | $71 | $6 |
| Glipizide | 11 | $62 | $6 |
| Simvastatin | 11 | $51 | $5 |
2019: 19 drugs
| Lantus Solostar | 38 | $27,844 | $733 |
| Jardiance | 22 | $24,952 | $1,134 |
| Humalog Kwikpen U-100 | 16 | $19,483 | $1,218 |
| Tradjenta | 13 | $16,238 | $1,249 |
| Toujeo Solostar | 12 | $11,877 | $990 |
| Januvia | 12 | $8,468 | $706 |
| Synthroid | 48 | $3,826 | $80 |
| Ultra-Fine Nano Pen Needle | 38 | $3,799 | $100 |
| Levothyroxine | 97 | $2,869 | $30 |
| Liothyronine | 34 | $2,751 | $81 |
| Metformin Hcl Er | 67 | $1,913 | $29 |
| Alendronate | 63 | $848 | $13 |
| Methimazole | 33 | $521 | $16 |
| Atorvastatin | 30 | $510 | $17 |
| Metformin | 22 | $315 | $14 |
| Simvastatin | 14 | $251 | $18 |
| Glipizide | 15 | $141 | $9 |
| Lisinopril | 16 | $111 | $7 |
| Amlodipine Besylate | 11 | $92 | $8 |
2018: 19 drugs
| Forteo | 12 | $52,094 | $4,341 |
| Humalog Kwikpen U-100 | 16 | $19,612 | $1,226 |
| Lantus Solostar | 28 | $18,491 | $660 |
| Toujeo Solostar | 11 | $6,627 | $602 |
| Humalog | 12 | $6,293 | $524 |
| Levothyroxine | 98 | $2,998 | $31 |
| Synthroid | 30 | $2,789 | $93 |
| Ultra-Fine Nano Pen Needle | 22 | $2,141 | $97 |
| Liothyronine | 22 | $1,616 | $73 |
| Nateglinide | 12 | $1,517 | $126 |
| Alendronate | 82 | $938 | $11 |
| Metformin Hcl Er | 40 | $773 | $19 |
| Hydrocortisone | 14 | $434 | $31 |
| Metformin | 26 | $327 | $13 |
| Atorvastatin | 16 | $290 | $18 |
| Glipizide | 21 | $242 | $12 |
| Losartan | 19 | $189 | $10 |
| Methimazole | 15 | $136 | $9 |
| Lisinopril | 11 | $77 | $7 |
2017: 17 drugs
| Forteo | 20 | $64,133 | $3,207 |
| Humalog Kwikpen U-100 | 16 | $18,163 | $1,135 |
| Lantus Solostar | 32 | $16,455 | $514 |
| Lantus | 12 | $5,850 | $487 |
| Humalog | 11 | $4,853 | $441 |
| Synthroid | 40 | $3,103 | $78 |
| Levothyroxine | 56 | $1,816 | $32 |
| Repaglinide | 20 | $1,717 | $86 |
| Raloxifene | 15 | $1,210 | $81 |
| Liothyronine | 15 | $908 | $61 |
| Alendronate | 78 | $699 | $9 |
| Ultra-Fine Mini Pen Needle | 13 | $658 | $51 |
| Insulin | 18 | $553 | $31 |
| Metformin Hcl Er | 21 | $500 | $24 |
| Metformin | 44 | $398 | $9 |
| Glipizide | 14 | $173 | $12 |
| Methimazole | 15 | $134 | $9 |
2016: 16 drugs
| Forteo | 31 | $77,094 | $2,487 |
| Lantus Solostar | 37 | $18,961 | $512 |
| Humalog Kwikpen U-100 | 14 | $15,958 | $1,140 |
| Lantus | 23 | $8,385 | $365 |
| Synthroid | 45 | $2,777 | $62 |
| Evista | 12 | $2,397 | $200 |
| Levothyroxine | 72 | $2,046 | $28 |
| Bd Ultra-Fine Pen Needle | 29 | $1,481 | $51 |
| Metformin Hcl Er | 23 | $1,227 | $53 |
| Alendronate | 104 | $872 | $8 |
| Insulin | 16 | $453 | $28 |
| Insulin | 17 | $426 | $25 |
| Metformin | 37 | $374 | $10 |
| Glipizide | 40 | $325 | $8 |
| Methimazole | 21 | $193 | $9 |
| Amlodipine Besylate | 20 | $108 | $5 |
2015: 14 drugs
| Lantus Solostar | 36 | $20,254 | $563 |
| Humalog Kwikpen U-100 | 24 | $15,164 | $632 |
| Lantus | 21 | $6,735 | $321 |
| Metformin Hcl Er | 21 | $5,478 | $261 |
| Repaglinide | 11 | $2,942 | $267 |
| Synthroid | 51 | $2,152 | $42 |
| Levothyroxine | 43 | $1,411 | $33 |
| Bd Ultra-Fine Pen Needle | 24 | $1,198 | $50 |
| Levoxyl | 19 | $467 | $25 |
| Alendronate | 51 | $442 | $9 |
| Metformin | 34 | $419 | $12 |
| Glipizide | 19 | $189 | $10 |
| Glimepiride | 12 | $59 | $5 |
| Hydrochlorothiazide | 13 | $31 | $2 |
2014: 12 drugs
| Forteo | 18 | $37,038 | $2,058 |
| Humalog | 36 | $16,344 | $454 |
| Lantus Solostar | 23 | $10,860 | $472 |
| Lantus | 28 | $9,205 | $329 |
| Actonel | 13 | $2,655 | $204 |
| Bd Ultra-Fine Pen Needle | 22 | $1,159 | $53 |
| Synthroid | 22 | $967 | $44 |
| Levothyroxine | 32 | $636 | $20 |
| Metformin | 32 | $345 | $11 |
| Glipizide | 21 | $244 | $12 |
| Glimepiride | 16 | $92 | $6 |
| Alendronate | 16 | $87 | $5 |
2013: 11 drugs
| Forteo | 15 | $19,534 | $1,302 |
| Humalog | 45 | $10,892 | $242 |
| Lantus Solostar | 12 | $3,173 | $264 |
| Lantus | 13 | $3,049 | $235 |
| Actonel | 11 | $1,574 | $143 |
| Synthroid | 14 | $573 | $41 |
| Glipizide | 26 | $292 | $11 |
| Levothyroxine | 17 | $250 | $15 |
| Metformin | 17 | $173 | $10 |
| Atorvastatin | 11 | $162 | $15 |
| Glimepiride | 12 | $78 | $7 |
Money from drug and device companies
$300 in 2019
A payment is not proof that care is biased.
| Tandem Diabetes Care | T-Slim Insulin Pump | $300 | 1 payment
|
See the published payment
| Tandem Diabetes Care | Paid to speak or teach · 2019-07-17 | T-Slim Insulin Pump | $300 |
Professional record
- NPI
- 1144420902
- Licence
- CA A99582California A99582: Current · expires 2026-09-30
- Trained
- University of California, San Francisco School of Medicine, 2005
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2007-07-20
- NPI last updated
- 2020-05-28
- NPI record certified
- 2020-05-28
This is when the NPI record was last certified, not a medical board exam.